Utah Medical Products

UTMD

Market cap $225M

UTMD's niche leadership, global footprint, and strong cash generation position it to benefit from rising demand for high-quality maternal and neonatal healthcare solutions.

American Express leads featured reports as spending growth and digital investments drive gains, while Intuitive Surgical and Shopify show mixed momentum.

UTMD's Q4 earnings fall year over year due to weak OEM sales and lower international Filshie sales, but strong U.S. Filshie growth and steady margins help offset broader revenue pressure.

SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on April 3, 2026 to stockholders of record at the close of business on March 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year.

SALT LAKE CITY, UT / ACCESS Newswire / November 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors.

Utah Medical's Q3 earnings fell 20% year over year as order cancellations and tariffs pressured margins. Growth in U.S. Filshie devices and direct sales helped partially offset declines.

SALT LAKE CITY, UT / ACCESS Newswire / October 23, 2025 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2025 financial results that were unusually hampered by global trade uncertainty. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.

Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.

SALT LAKE CITY, UT / ACCESS Newswire / July 29, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on October 2, 2025 to stockholders of record at the close of business on September 17, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.

Utah Medical Products Reports Q2 Decline